Literature DB >> 6622881

Successful treatment of human non-24-hour sleep-wake syndrome.

B Kamgar-Parsi, T A Wehr, J C Gillin.   

Abstract

The authors report a case in which a non-24-h (hypernychthemeral) sleep-wake cycle appeared as a late complication of a more fundamental disturbance in the quality of sleep (difficulty falling asleep, frequent awakenings, nonrefreshing sleep). The sleep disturbance began abruptly after a series of stressful events. The patient reported that he extended his hours of bedrest in the morning in order to increase his total sleep time and feel mor rested, and that he gradually extended his hours of activity in the late evening in order to increase his drowsiness and ability to fall asleep. At first this behavior, which was a deliberate attempt to compensate for inefficient nighttime sleep, led to a delayed sleep period, as also occurs in the delayed sleep phase syndrome. After several years in which sleep efficiency progressively deteriorated, this behavior led to a non-24-h free-running sleep-wake cycle. After the patient was treated with thyroxine for borderline hypothyroidism, and then flurazepam and finally vitamin B12, his sleep disturbance progressively improved and his sleep-wake cycle shortened. After B12 treatment he was able to advance the timing of ;his sleep period for the first time in nearly 10 years and to follow a normal 24-h sleep-wake regimen.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6622881     DOI: 10.1093/sleep/6.3.257

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  10 in total

1.  The delayed sleep phase syndrome: clinical and investigative findings in 14 subjects.

Authors:  B Alvarez; M J Dahlitz; J Vignau; J D Parkes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

2.  Vitamin B12 amplifies circadian phase shifts induced by a light pulse in rats.

Authors:  M Ikeda; K Honda; S Inoué
Journal:  Experientia       Date:  1996-07-15

3.  Antidepressant drugs can slow or dissociate circadian rhythms.

Authors:  A Wirz-Justice; I C Campbell
Journal:  Experientia       Date:  1982-11-15

4.  Therapeutics for Circadian Rhythm Sleep Disorders.

Authors:  Ehren R Dodson; Phyllis C Zee
Journal:  Sleep Med Clin       Date:  2010-12

5.  Circadian rhythm sleep disorders.

Authors:  Lirong Zhu; Phyllis C Zee
Journal:  Neurol Clin       Date:  2012-11       Impact factor: 3.806

6.  Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015: An American Academy of Sleep Medicine Clinical Practice Guideline.

Authors:  R Robert Auger; Helen J Burgess; Jonathan S Emens; Ludmila V Deriy; Sherene M Thomas; Katherine M Sharkey
Journal:  J Clin Sleep Med       Date:  2015-10-15       Impact factor: 4.062

7.  Effects of vitamin B12 on plasma melatonin rhythm in humans: increased light sensitivity phase-advances the circadian clock?

Authors:  K Honma; M Kohsaka; N Fukuda; N Morita; S Honma
Journal:  Experientia       Date:  1992-08-15

8.  Non-24-hour sleep-wake syndrome improved by low-dose valproic acid: a case report.

Authors:  Masatake Kurita; Takahiro Moriya; Satoshi Nishino; Eishin Hirata; Noriyasu Hirasawa; Yoshiro Okubo; Tadahiro Sato
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-13       Impact factor: 2.570

9.  Lack of association between serum vitamin B12 and nocturnal sleep parameters following cyanocobalamin supplementation in healthy adults.

Authors:  Toshiba Channer-Wallen; Paula Dawson; Peta-Gaye Thomas-Brown; Maxine Gossell-Williams
Journal:  Heliyon       Date:  2022-01-25

10.  Allostatic adaptation and personalized physiological trade-offs in the circadian regulation of the HPA axis: A mathematical modeling approach.

Authors:  Rohit Rao; Ioannis P Androulakis
Journal:  Sci Rep       Date:  2019-08-01       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.